CDK4 and neoplasm: The fact that abnormal PI3K-mTOR as well as MAPK signaling are observed in multiple tumor types that exhibit do novo or acquired resistance to CDK4/6 inhibitors [reviewed in 191, 192] suggests that targeting these pathways might be of significant clinical value.